Drug Trial Radar · NCT05486598
A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
16
Planned (sponsor's estimate)
Start
Jun 21, 2022
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Main study objective: the pharmacokinetic effects of high-fat diet on AL8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects. Secondary study objectives: safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects
Conditions
- Diet, High-Fat
- Pharmacokinetics
Interventions
AL8326 tabletsDrug
Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals. Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-tTime frame: 120 hours after each dose
- AUC0-∞Time frame: 120 hours after each dose
- CmaxTime frame: 120 hours after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.